Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATNF 
180 Life Sciences Corp (ATNF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ATNF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.02M USD | Price to earnings Ratio 0.12 | 1Y Target Price 80 |
Price to earnings Ratio 0.12 | 1Y Target Price 80 | ||
Volume (30-day avg) 61253 | Beta 0.21 | 52 Weeks Range 0.90 - 8.00 | Updated Date 04/1/2025 |
52 Weeks Range 0.90 - 8.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 7.98 |
Earnings Date
Report Date 2025-03-20 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.62% | Return on Equity (TTM) -174.19% |
Valuation
Trailing PE 0.12 | Forward PE 6.08 | Enterprise Value 6175268 | Price to Sales(TTM) - |
Enterprise Value 6175268 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.46 | Shares Outstanding 3177000 | Shares Floating 1400407 |
Shares Outstanding 3177000 | Shares Floating 1400407 | ||
Percent Insiders 18.14 | Percent Institutions 21.32 |
Analyst Ratings
Rating 5 | Target Price 80 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
180 Life Sciences Corp
Company Overview
History and Background
180 Life Sciences Corp. was formed through a reverse merger in 2020, focusing on inflammatory diseases and unmet medical needs. Its research originates from discoveries made at universities.
Core Business Areas
- Fibrosis & Anti-TNF: Developing therapies targeting fibrosis and exploring alternative treatments for conditions where anti-TNF drugs are ineffective.
- Early-Stage Inflammatory Diseases: Focusing on early-stage inflammatory diseases, aiming to halt or reverse disease progression.
Leadership and Structure
Dr. James Woody serves as CEO. The company has a scientific advisory board and a management team focused on clinical development and commercialization.
Top Products and Market Share
Key Offerings
- Anti-TNF Fibrosis Therapy: Developing a therapy to address fibrosis in patients who do not respond to anti-TNF drugs. Market share is currently N/A (pre-commercialization). Competitors: Major pharmaceutical companies with existing anti-TNF drugs (e.g., AbbVie, Johnson & Johnson).
- Early-Stage Dupuytren's Contracture Treatment: Developing a therapy for early-stage Dupuytren's Contracture, targeting inflammation to prevent disease progression. Market share is currently N/A (pre-commercialization). Competitors: Collagenase clostridium histolyticum (Xiaflex), surgery.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and research-intensive, with a focus on developing novel therapies for unmet medical needs. The market is characterized by high risk and high reward potential.
Positioning
180 Life Sciences Corp. is positioned as a clinical-stage biotechnology company focusing on specific inflammatory diseases. Its competitive advantage lies in its targeted approach and intellectual property.
Total Addressable Market (TAM)
The TAM for anti-TNF non-responders and Dupuytren's Contracture is estimated to be in the billions of dollars. 180 Life Sciences is positioned to capture a portion of this market with successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Focused research on specific inflammatory diseases
- Strong scientific advisory board
- Proprietary technology
- Addressing unmet medical needs
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Pre-commercialization stage
- High cash burn
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new disease areas
- FDA approval and commercialization
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- BMY
Competitive Landscape
180 Life Sciences faces intense competition from established pharmaceutical companies with greater resources. Its success depends on demonstrating superior efficacy and safety in its clinical trials.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the pre-commercialization stage.
Future Projections: Future growth is dependent on the success of clinical trials and potential commercialization of its therapies. Analyst estimates are highly variable.
Recent Initiatives: Recent initiatives include advancing clinical trials for Dupuytren's Contracture and exploring new applications of its technology.
Summary
180 Life Sciences is a speculative investment due to its pre-commercialization status. Successful clinical trials are crucial for its long-term viability. The company's focused research and strong scientific advisory board are strengths, but limited financial resources and competition pose significant challenges.
Similar Companies
AGEN
Agenus Inc
AGEN
Agenus Inc
CYTK
Cytokinetics Inc
CYTK
Cytokinetics Inc
VIRX
Viracta Therapeutics Inc
VIRX
Viracta Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports.
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment in biotechnology companies is highly speculative and carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 180 Life Sciences Corp
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2017-06-27 | CEO & Director Mr. Lloyd Blair Jordan L.L.B., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://180lifesciences.com |
Full time employees 4 | Website https://180lifesciences.com | ||
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.